Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MRD surveillance can detect relapse before imaging in early-stage NSCLC

Key clinical point: Minimal residual disease surveillance after surgery can detect relapse in advance of imaging in patients with early-stage non-small cell lung cancer.

Major finding: Relapse occurred in 9 of 10 patients who tested positive for minimal residual disease but had no evidence of relapse via imaging.

Study details: An analysis of data from the TRACERx study, including 53 patients who relapsed and 37 who did not.

Disclosures: TRACERx is funded by University College London in collaboration with Cancer Research UK. Dr. Abbosh disclosed relationships with AstraZeneca, Novartis, Roche Diagnostics, Bristol Myers Squibb, Achilles Therapeutics, and Archer Diagnostics.

Citation:

Abbosh C et al. AACR 2020, Abstract CT023.